Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The aim of this paper is to critically analyze the composition of many inositol-based products currently used to treat Polycystic Ovary Syndrome (PCOS). Several different combinations of myo-inositol and D-chiro-inositol, with and without additional compounds such as micro- and macroelements, vitamins, and alpha-lipoic acid, have been formulated over the years. Such therapeutic proposals do not take various features of inositol stereoisomers into consideration. As an example, it is important to know that D-chiro-inositol treatment may be beneficial when administered in low doses, yet the progressive increase of its dosage results in the loss of its advantageous effects on the reproductive performance of women and a deterioration in the quality of blastocysts created via in vitro fertilization (IVF). In addition, we have to consider that the intestinal absorption of myo-inositol is reduced by the simultaneous administration of D-chiro-inositol since the two stereoisomers compete with each other for the same transporter that has similar affinity for each of them. A decrease in myo-inositol absorption is also found when it is coadministered with inhibitors of sugar intestinal absorption and/or types of sugars such as sorbitol, maltodextrin, and sucralose. The combination of these may require higher amounts of myo-inositol in order to reach a therapeutic dosage compared to inositol administration alone, a particularly important fact when physicians strive to obtain a specific plasma level of the stereoisomer. Finally, we must point out that D-chiro-inositol was found to be an aromatase inhibitor which increases androgens and may have harmful consequences for women. Therefore, the inositol supplements used in PCOS treatment must be carefully defined. Clinical evidence has demonstrated that the 40 : 1 ratio between myo-inositol and D-chiro-inositol is the optimal combination to restore ovulation in PCOS women. Therefore, it is quite surprising to find that inositol-based treatments for PCOS seem to be randomly chosen and are often combined with useless or even counterproductive molecules, all of which can weaken myo-inositol’s efficacy. Such treatments clearly lack therapeutic rationale.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ovulatory and Metabolic Effects of d-Chiro-Inositol in the Polycystic Ovary Syndrome
Nestler, J. E., Jakubowicz, D. J., Reamer, P., Gunn, R. D., & Allan, G. (1999) · New England Journal of Medicine · doi:10.1056/nejm199904293401703 · Cited by 518 · cited 3×
“DCI administration also resulted in ovulation in 19 of 22 women (86%), whereas only 6 of 22 women (27%) ovulated in the placebo group [14].”
BackgroundResultGenazzani, A. D., Lanzoni, C., Ricchieri, F., & Jasonni, V. M. (2008) · Gynecological Endocrinology · doi:10.1080/09513590801893232 · Cited by 221
Effects of d-chiro-inositol in lean women with the polycystic ovary syndrome
Iuorno, M. J., Jakubowicz, D. J., Baillargeon, J.-P., Dillon, P., Gunn, R. D., Allan, G., & Nestler, J. E. (2002) · Endocrine Practice · doi:10.4158/ep.8.6.417 · Cited by 188 · cited 3×
“In 1998, before the study publication, Insmed Pharmaceuticals had obtained a US patent claiming the effectiveness of DCI in the treatment of PCOS and, in 2002, a follow-up study was performed by the same group in lean women with PCOS [15].”
BackgroundResultArtini, P. G., Di Berardino, O. M., Papini, F., Genazzani, A. D., Simi, G., Ruggiero, M., & Cela, V. (2013) · Gynecological Endocrinology · doi:10.3109/09513590.2012.743020 · Cited by 154
Sun, T.-H., Heimark, D. B., Nguygen, T., Nadler, J. L., & Larner, J. (2002) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(02)00313-3 · Cited by 144 · cited 1×
“MI can be transformed into DCI by a specific NAD/ NADH-dependent epimerase, which is unidirectional and is stimulated by insulin [3, 4].”
BackgroundSchneider, S. (2015) · FEBS Letters · doi:10.1016/j.febslet.2015.03.012 · Cited by 118 · cited 3×
“Although the absorption of MI can occur by a diffusion process at high MI concentrations, the uptake of inositols by cells is primarily carried out by a complex system of transporters (SMIT1, SMIT2, and HMIT) which mediate an active transport of inositols [46].”
BackgroundInfluentialUnfer, V., Carlomagno, G., Papaleo, E., Vailati, S., Candiani, M., & Baillargeon, J.-P. (2014) · Reproductive Sciences · doi:10.1177/1933719113518985 · Cited by 105 · cited 1×
“plasma ratio of MI to DCI is 40 :1 [6], while in ovarian follicular fluid the ratio is close to 100 :1 [7].”
BackgroundBenelli, E., Del Ghianda, S., Di Cosmo, C., & Tonacchera, M. (2016) · International Journal of Endocrinology · doi:10.1155/2016/3204083 · Cited by 100
Pizzo, A., Laganà, A. S., & Barbaro, L. (2014) · Gynecological Endocrinology · doi:10.3109/09513590.2013.860120 · Cited by 90
(2019) · PubMed · doi:10.26355/eurrev_201906_18223 · Cited by 75
Cited by
Inositols: From Established Knowledge to Novel Approaches
Dinicola, S., Unfer, V., Facchinetti, F., Soulage, C. O., Greene, N. D., Bizzarri, M., Laganà, A. S., Chan, S.-Y., Bevilacqua, A., Pkhaladze, L., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910575 · Cited by 154
“Although other ratios were analyzed, these combinations were without a scientific rationale [51]; conversely the 40:1 ratio that may appear arbitrary, actually is similar to the plasma ratio reported in healthy women [51–54], thus supporting its supplementation to restore the physiological concentrations of myo-Ins an…”
ResultSelf-citationKamenov, Z., & Gateva, A. (2020) · Molecules · doi:10.3390/molecules25235566 · Cited by 100
“On the other hand DCI was found to be an aromatase inhibitor which increases androgens and may have harmful consequences for normal ovulatory function [115].”
BackgroundMendoza, N., Diaz-Ropero, M. P., Aragon, M., Maldonado, V., Llaneza, P., Lorente, J., Mendoza-Tesarik, R., Maldonado-Lobon, J., Olivares, M., & Fonolla, J. (2019) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1576620 · Cited by 36
Current and emerging drug treatment strategies for polycystic ovary syndrome
Helvaci, N., & Yildiz, B. O. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2022.2108702 · Cited by 35
“Thus, supplementation of inositols has been proposed as treatment owing to their potential role in improving endocrine and metabolic outcomes in PCOS patients [39].”
BackgroundKachhawa, G., Senthil Kumar, K. V., Kulshrestha, V., Khadgawat, R., Mahey, R., & Bhatla, N. (2022) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.13971 · Cited by 18
Metadata
- Authors
- Roseff, S., & Montenegro, M.
- Venue
- International Journal of Endocrinology
- Publisher
- Wiley
- Published
- 2020-03-27
- Volume
- 2020
- Pages
- 1-8
- ISSN
- 1687-8337 (ISSN-L)
- 1687-8345
- OpenAlex
- W3013761037
- Cited by
- 49
- References
- 13
- FWCI
- 4.34
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary. https://app.cochat.ai/papers/10.1155/2020/6461254
- The paper
- Roseff, S., & Montenegro, M. (2020). Inositol Treatment for PCOS Should Be Science-Based and Not Arbitrary. International Journal of Endocrinology. https://doi.org/10.1155/2020/6461254
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.